0001209191-19-031530.txt : 20190520 0001209191-19-031530.hdr.sgml : 20190520 20190520183555 ACCESSION NUMBER: 0001209191-19-031530 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190516 FILED AS OF DATE: 20190520 DATE AS OF CHANGE: 20190520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAZANCHYAN ANNA CENTRAL INDEX KEY: 0001369219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 19840375 MAIL ADDRESS: STREET 1: 933 MAMARONECK AVENUE STREET 2: SUITE 103 CITY: MAMARONECK STATE: NY ZIP: 10543 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-05-16 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001369219 KAZANCHYAN ANNA C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLTZMAN STREET REHOVOT L3 ISRAEL 1 0 0 0 Ordinary Shares 2019-05-16 4 A 0 28195 0.00 A 55955 D Ordinary Shares 2019-05-20 4 S 0 10600 2.61 D 45355 D This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.57 to $2.68 inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. /s/ Mutya Harsch as attorney-in-fact for Anna Kazanchyan 2019-05-20